Company research
Loading SEC business and financials…
AI relationship research has not yet been verified for this company.
Listing data synced 2026-04-16.
Loading your outlook…
Loading…
Loading company activity...
Estimated market cap
Unavailable
A supported share count and cached closing price are required.
Annual report for the year ended 2025-12-31. These are reported annual figures, not trailing twelve-month estimates.
SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with our lead program in the treatment and prevention of difficult-to-treat and drug-resistant fungal infections. We are developing our proprietary antifungal platform “fungerps”, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a broad range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis , Coccidioides , Histoplasma and Blastomyces genera and most common mucorales species.
Excerpt from Item 1 — Business; filed 2026-03-04. May be shortened.
Source: SEC Company Facts. Checked 2026-10-05. Data is refreshed in the background. Missing or ambiguous figures are left unavailable.
